UC Davis Health Clinical Studies

A Study of the Effect of an Oral Vaccine on the Digestive System

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to: 1. Determine whether ingesting the standard, 4-doses of a live, weakened typhoid fever vaccine will cause a temporary leaky gut and inflammation. Leaky gut is a condition when the gut lining becomes more permeable, or “leaky”, for substances in the gut to pass through to the tissues beneath it. 2. Compare the gut leakiness caused by this vaccine to the gut leakiness caused by a short-term ingestion of aspirin. 3. Examine whether the size of the body’s natural immune response to this vaccine is associated with gut leakiness and inflammation of similar size.

Biological study, Phase 1
Female, age 18 to 49 years old

Online Developmental Screening Study

Have you had a new baby? Learn about your baby's development!

Researchers at the UC Davis MIND Institute on the UC Davis Medical Center campus in Sacramento are conducting an online study tracking the development of infants from 6 to 36 months of age. The goal of the study is to help parents understand their child’s development and gain access to resources when needed. This study tests new online methods of tracking developmental milestones in babies. The UC Davis MIND Institute is a collaborative international research center, committed to the awareness, understanding, prevention and care of neurodevelopmental disorders.

Longitudinal screening study
Any, age 6 months

A Study of Experimental Pembrolizumab (MK-3475) in Combination With Chemotherapy & Endocrine Therapy for Breast Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to: o Test the safety of the study drug, pembrolizumab (MK-3475), with certain types of chemotherapy and endocrine therapy. o See how well the study drug, pembrolizumab, works when combined with chemotherapy and endocrine therapy. o To see if combining the study drug with chemotherapy will have a positive outcome on your surgery, compared to these treatments alone. o To see if combining the study drug with chemotherapy and endocrine therapy keeps your cancer from returning sooner. o To see if combining the study drug with chemotherapy and endocrine therapy helps you live longer. o See how your body handles the study drug. This is a study to test Pembrolizumab for your type of breast cancer. It has not been approved by the FDA to treat breast cancer, but it is approved to treat other types of cancer. The chemotherapies being used in this study (Paclitaxel, Doxorubicin, Epirubicin and Cyclophosphamide) are approved. They are widely used, as a treatment for your type of breast cancer. Endocrine therapy is also approved to treat your type of breast cancer. You will receive endocrine therapy as part of your treatment during the study. The use of these drugs together with pembrolizumab is experimental. “Experimental” means that the study drug is currently being tested. It is not approved by the U.S. FDA

Biological study, Phase 3
Any, age 18 years or older
Loading